BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

60 related articles for article (PubMed ID: 19958394)

  • 1. Six-minute walk test in scleroderma-associated pulmonary arterial hypertension: are we counting what counts?
    Pamidi S; Mehta S
    J Rheumatol; 2009 Feb; 36(2):216-8. PubMed ID: 19208554
    [No Abstract]   [Full Text] [Related]  

  • 2. Limitations to the 6-minute walk test in interstitial lung disease and pulmonary hypertension in scleroderma.
    Garin MC; Highland KB; Silver RM; Strange C
    J Rheumatol; 2009 Feb; 36(2):330-6. PubMed ID: 19208563
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Exercise as an end-point in pulmonary hypertension trials.
    McCullagh B; Girgis RE
    Int J Clin Pract Suppl; 2010 Jan; (165):4-6. PubMed ID: 19958394
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Endpoints in pulmonary arterial hypertension: the role of clinical worsening.
    Peacock A; Keogh A; Humbert M
    Curr Opin Pulm Med; 2010 May; 16 Suppl 1():S1-9. PubMed ID: 20375659
    [TBL] [Abstract][Full Text] [Related]  

  • 5. End-points and clinical trial design in pulmonary arterial hypertension: have we made progress?
    Peacock AJ; Naeije R; Galiè N; Rubin L
    Eur Respir J; 2009 Jul; 34(1):231-42. PubMed ID: 19567606
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pulmonary arterial hypertension: evaluation of the newly diagnosed patient.
    Torbicki A; Kurzyna M
    Semin Respir Crit Care Med; 2005 Aug; 26(4):372-8. PubMed ID: 16121313
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The need to move from 6-minute walk distance to outcome trials in pulmonary arterial hypertension.
    Gaine S; Simonneau G
    Eur Respir Rev; 2013 Dec; 22(130):487-94. PubMed ID: 24293464
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diagnostics in pulmonary hypertension.
    Schannwell CM; Steiner S; Strauer BE
    J Physiol Pharmacol; 2007 Nov; 58 Suppl 5(Pt 2):591-602. PubMed ID: 18204173
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Perspective on the optimal endpoints for pulmonary arterial hypertension trials.
    Rubin L; Simonneau G
    Curr Opin Pulm Med; 2010 May; 16 Suppl 1():S43-6. PubMed ID: 20375664
    [TBL] [Abstract][Full Text] [Related]  

  • 10.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 11.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 12.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 13.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 14.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.